SI2816118T1 - Metode za dostavo genov - Google Patents

Metode za dostavo genov

Info

Publication number
SI2816118T1
SI2816118T1 SI200632301T SI200632301T SI2816118T1 SI 2816118 T1 SI2816118 T1 SI 2816118T1 SI 200632301 T SI200632301 T SI 200632301T SI 200632301 T SI200632301 T SI 200632301T SI 2816118 T1 SI2816118 T1 SI 2816118T1
Authority
SI
Slovenia
Prior art keywords
methods
delivering genes
genes
delivering
Prior art date
Application number
SI200632301T
Other languages
English (en)
Inventor
Linda May Rothblum Watkins
Travis Hughes
Raymond A. Chavez
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of SI2816118T1 publication Critical patent/SI2816118T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200632301T 2005-05-31 2006-05-26 Metode za dostavo genov SI2816118T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68632405P 2005-05-31 2005-05-31
EP14181383.2A EP2816118B1 (en) 2005-05-31 2006-05-26 Methods for delivering genes

Publications (1)

Publication Number Publication Date
SI2816118T1 true SI2816118T1 (sl) 2019-01-31

Family

ID=37420968

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632301T SI2816118T1 (sl) 2005-05-31 2006-05-26 Metode za dostavo genov

Country Status (12)

Country Link
US (2) US8524678B2 (sl)
EP (2) EP1885863B1 (sl)
CY (1) CY1120856T1 (sl)
DK (1) DK2816118T3 (sl)
ES (1) ES2696824T3 (sl)
HK (1) HK1117871A1 (sl)
HU (1) HUE041875T2 (sl)
LT (1) LT2816118T (sl)
PL (1) PL2816118T3 (sl)
PT (1) PT2816118T (sl)
SI (1) SI2816118T1 (sl)
WO (1) WO2006130581A2 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2012158757A1 (en) 2011-05-16 2012-11-22 The Trustees Of The University Of Pennsylvania Proviral plasmids for production of recombinant adeno-associated virus
US10512672B2 (en) 2013-07-18 2019-12-24 Xalud Therapeutics, Inc. Methods for the treatment of inflammatory joint disease
CA2924013A1 (en) 2013-11-05 2015-05-14 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
US11273227B2 (en) * 2015-10-09 2022-03-15 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating Stargardt's disease and other ocular disorders
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
MA50096A (fr) * 2017-09-08 2020-07-15 Generation Bio Co Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
MX2020008676A (es) * 2018-02-22 2020-09-25 Generation Bio Co Expresion controlada de transgenes mediante el uso de vectores de adn de extremo cerrado (ceadn).
EP4189098A1 (en) 2020-07-27 2023-06-07 Anjarium Biosciences AG Compositions of dna molecules, methods of making therefor, and methods of use thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
WO1995003411A1 (en) 1993-07-26 1995-02-02 Schering Corporation Agonists and antagonists of human interleukin-10
US6652850B1 (en) * 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1995024425A1 (en) 1994-03-11 1995-09-14 Board Of Regents, The University Of Texas System Immunomodulatory trichinella substances
SK283096B6 (sk) 1994-07-05 2003-02-04 Steeno Research Group A/S Imunomodulátory
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5549127A (en) 1995-05-03 1996-08-27 Chang; Wen-Hsiung Spring fixing structure for a hairgrip
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
PT1445322E (pt) 1995-06-15 2010-01-19 Crucell Holland Bv Sistemas de empacotamento para adenovírus recombinante humano destinados a terapia genética
US5753895A (en) 1996-01-16 1998-05-19 Golden Valley Microwave Foods, Inc. Microwave popcorn package with adhesive pattern
BR9713632A (pt) 1996-12-23 2000-04-11 Schering Corp Citocina de mamìfero relacionada com a il-10
US6233483B1 (en) 1997-05-14 2001-05-15 Pacesetter, Inc. System and method for generating a high efficiency biphasic defibrillation waveform for use in an implantable cardioverter/defibrillator (ICD).
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU3063899A (en) 1998-03-17 1999-10-11 Schering Corporation Use of il-10 to treat major depressive disorder
AU752658B2 (en) 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
DE69929600T2 (de) 1998-05-27 2006-09-07 Avigen Inc., Alameda Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
EP1144009B1 (en) 1998-12-03 2002-10-23 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
EP1148885A4 (en) 1999-02-08 2002-05-08 Chiron Corp ELECTRICALLY INDUCED INCREASE IN IMMUNITY AND EFFECTIVENESS OF IN VIVO DNA VACCINES
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
ES2530857T3 (es) 1999-04-28 2015-03-06 Genetics Inst Llc Proteínas GIL-19/AE289 humanas y polinucleótidos que codifican las mismas
US6165754A (en) * 1999-06-08 2000-12-26 Cornell Research Foundation, Inc. Method of expressing an exogenous nucleic acid
AU7346100A (en) 1999-09-02 2001-03-26 University Of Medicine And Dentistry Of New Jersey Cytomegalovirus-encoded il-10 homolog
US20010049357A1 (en) 1999-12-03 2001-12-06 De Asit K. Use of Hsp27 as an anti-inflammatory agent
AU2002217929A1 (en) * 2000-11-28 2002-06-11 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
CA2361462A1 (en) 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2006119170A2 (en) 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
EP1891103B1 (en) 2005-05-31 2009-12-23 The Regents of the University of Colorado Mutant il-10

Also Published As

Publication number Publication date
WO2006130581A2 (en) 2006-12-07
EP1885863B1 (en) 2014-11-19
EP2816118B1 (en) 2018-10-17
PT2816118T (pt) 2018-11-28
ES2696824T3 (es) 2019-01-18
US20090208563A1 (en) 2009-08-20
EP1885863A2 (en) 2008-02-13
US8524678B2 (en) 2013-09-03
PL2816118T3 (pl) 2019-03-29
HK1117871A1 (en) 2009-01-23
HUE041875T2 (hu) 2019-06-28
EP2816118A1 (en) 2014-12-24
WO2006130581A3 (en) 2007-03-22
LT2816118T (lt) 2018-12-10
US20130337556A1 (en) 2013-12-19
DK2816118T3 (en) 2018-12-03
CY1120856T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
SI2816118T1 (sl) Metode za dostavo genov
GB2476188B (en) Evaluating genetic disorders
ZA200709897B (en) Improved methods controlling gene expression
GB0512707D0 (en) Gene expression technique
ZA200900910B (en) Dressed leather
GB2441963B (en) Height-Adjusting Apparatus
IL198354A0 (en) Genetic variations associated with tumors
EP2142106A4 (en) DEVICE FOR DISTRIBUTING CLAMPS FROM A FORM MEMORY ALLOY
GB0613209D0 (en) Methods
GB0600967D0 (en) Methods
GB0601979D0 (en) Rests
GB0608941D0 (en) Methods
EP2115136A4 (en) NOVEL PROCEDURE
GB0525523D0 (en) Genetic process
GB0607377D0 (en) Novel Methods
IL184372A (en) Method for providing interferon ß
EP2094718A4 (en) METHOD FOR RNA DESILYLATION
GB0417107D0 (en) Genes II
GB0508503D0 (en) Genes III
GB0611208D0 (en) Methods
GB0624391D0 (en) Methods
GB0606198D0 (en) Methods
GB0625194D0 (en) Methods
GB0606432D0 (en) Methods
GB0618836D0 (en) Methods